Corvus Pharmaceuticals Inc (NASDAQ:CRVS) surged higher Friday on an abnormally high volume. The stock may trade higher after favorable data results due to: AstraZeneca PLC (NASDAQ: AZN) for patients with unresectable, stage 3 non-small cell lung cancer.
The average session volume over a 100-day period is approximately 300,000. Friday’s session volume approached 120 million at the time of publication.
AZN news: AstraZeneca announced that “the COAST Phase II study showed that oleclumab, a monoclonal anti-CD73 antibody, or monalizumab, a monoclonal antibody against NKG2A, in combination with Imfinzi (durvalumab) improved progression-free survival and objective response rate compared to only Imfinzi in patients with unresectable, stage III non-small cell lung cancer who had not progressed after concomitant chemoradiation therapy.”
The results could positively impact Corvus Pharmaceuticals, which has a CD73 asset in the pipeline.
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company developing drugs and antibodies that target the most critical cellular elements of the immune system.
CRVS Price Promotion: Corvus Pharmaceuticals has traded as high as $5.74 and as low as $1.86 in a 52-week period.
The stock was up 72.60% to $3.90 at the time of publication.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.